| Time | Topics | Speaker/s |
|
16:30
-
16:35
|
Safety and Bioavailability of Complete and Half Dose Intravitreal Ziv-Aflibercept Injection in an Experimental Model: Contralateral Eye Study
|
Mojtaba Abrishami, MD
|
|
16:37
-
16:42
|
Pars Plana Vitrectomy vs Observation for Vitreomacular Traction Syndrome
|
Araz Mohamadzadeh, MD
|
|
16:44
-
16:49
|
The Rate of Endophthalmitis after Pars Plana Vitrectomy and Its Risk Factors
|
Ali Tabatabaei, MD
|
|
16:51
-
16:56
|
Geriatric Open Globe Injuries
|
Ali Tabatabaei, MD
|
|
16:58
-
17:03
|
One-Year Results of a Trial Comparing Two Doses of Intravitreal Ziv-Aflibercept vs Bevacizumab for Treatment of Diabetic Macular Edema
|
Mohammadhossein Jabbarpourbonyadi, MD
|
|
17:05
-
17:10
|
Association of Risk Genotypes of ARMS2/LOC387715 A69S and CFH Y402H With Age-Related Macular Degeneration With and Without Reticular Pseudodrusen: A Meta-Analysis
|
Mohammadhossein Jabbarpourbonyadi, MD
|
|
17:12
-
17:17
|
Association of Polymorphisms of Complement Factor I Rs141853578 (G119R) With Age-Related Macular Degeneration in an Iranian Population
|
Mohammadhossein Jabbarpourbonyadi, MD
|
|
17:19
-
17:24
|
Retinopathy of Prematurity (ROP): A 7-Year Review of Treated Premature Infants
|
Shokufeh Tavassoli, MD
|
|
17:26
-
17:31
|
Comparison Between Intravitreal Bevacizumab and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity: A Retrospective Analysis
|
Hamid Riazi Esfahani, MD
|
|
17:33
-
17:38
|
Ru-106 Plaque Radiotherapy Versus Non-Radiation Treatments for Vasoproliferative Tumors (Vpts) of Retina: A 15 Years’ Single Center Experience in IRAN
|
Navid Abolfathzadeh, MD
|
|
17:40
-
17:45
|
The Effect of Topical 2% Cyclosporine for the Treatment of Acute Anterior Uveitis: Is There a Place for Topical Cyclosporine in Uveitis?
|
Seyedeh Maryam Hosseini, MD
|
|
17:47
-
17:52
|
Intravitreal Diclofenac for Treatment of Refractory Uveitis-Associated Cystoid Macular Edema: A Before and after Clinical Study
|
Farzan Kianersi, MD
|